Literature DB >> 25400446

Gut microbiota-related complications in cirrhosis.

Isabel Gómez-Hurtado1, José Such1, Yolanda Sanz1, Rubén Francés1.   

Abstract

Gut microbiota plays an important role in cirrhosis. The liver is constantly challenged with commensal bacteria and their products arriving through the portal vein in the so-called gut-liver axis. Bacterial translocation from the intestinal lumen through the intestinal wall and to mesenteric lymph nodes is facilitated by intestinal bacterial overgrowth, impairment in the permeability of the intestinal mucosal barrier, and deficiencies in local host immune defences. Deranged clearance of endogenous bacteria from portal and systemic circulation turns the gut into the major source of bacterial-related complications. Liver function may therefore be affected by alterations in the composition of the intestinal microbiota and a role for commensal flora has been evidenced in the pathogenesis of several complications arising in end-stage liver disease such as hepatic encephalopathy, splanchnic arterial vasodilatation and spontaneous bacterial peritonitis. The use of antibiotics is the main therapeutic pipeline in the management of these bacteria-related complications. However, other strategies aimed at preserving intestinal homeostasis through the use of pre-, pro- or symbiotic formulations are being studied in the last years. In this review, the role of intestinal microbiota in the development of the most frequent complications arising in cirrhosis and the different clinical and experimental studies conducted to prevent or improve these complications by modifying the gut microbiota composition are summarized.

Entities:  

Keywords:  Bacterial translocation; Cirrhosis; Encephalopathy; Microbiota; Portal hypertension; Spontaneous bacterial peritonitis

Mesh:

Substances:

Year:  2014        PMID: 25400446      PMCID: PMC4229527          DOI: 10.3748/wjg.v20.i42.15624

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  100 in total

Review 1.  The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension.

Authors:  Thomas D Boyer; Ziv J Haskal
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

2.  Ascitic fluid and serum cefotaxime and desacetyl cefotaxime levels in patients treated for bacterial peritonitis.

Authors:  B A Runyon; E A Akriviadis; F R Sattler; J Cohen
Journal:  Dig Dis Sci       Date:  1991-12       Impact factor: 3.199

3.  Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial.

Authors:  Nitin Gupta; Ashish Kumar; Praveen Sharma; Vishal Garg; Barjesh C Sharma; Shiv K Sarin
Journal:  Liver Int       Date:  2013-04-21       Impact factor: 5.828

4.  Characterization of fecal microbial communities in patients with liver cirrhosis.

Authors:  Yanfei Chen; Fengling Yang; Haifeng Lu; Baohong Wang; Yunbo Chen; Dajiang Lei; Yuezhu Wang; Baoli Zhu; Lanjuan Li
Journal:  Hepatology       Date:  2011-06-26       Impact factor: 17.425

5.  Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study.

Authors:  Javier Fernández; Juan Acevedo; Miriam Castro; Orlando Garcia; Carlos Rodríguez de Lope; Daria Roca; Marco Pavesi; Elsa Sola; Leticia Moreira; Anibal Silva; Tiago Seva-Pereira; Francesco Corradi; Jose Mensa; Pere Ginès; Vicente Arroyo
Journal:  Hepatology       Date:  2012-04-04       Impact factor: 17.425

6.  Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites.

Authors:  C Guarner; B A Runyon; S Young; M Heck; M Y Sheikh
Journal:  J Hepatol       Date:  1997-06       Impact factor: 25.083

7.  Amoxicillin-clavulanic acid versus cefotaxime in the therapy of bacterial infections in cirrhotic patients.

Authors:  E Ricart; G Soriano; M T Novella; J Ortiz; M Sàbat; L Kolle; J Sola-Vera; J Miñana; J M Dedéu; C Gómez; J L Barrio; C Guarner
Journal:  J Hepatol       Date:  2000-04       Impact factor: 25.083

8.  Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis.

Authors:  B Bernard; J D Grangé; E N Khac; X Amiot; P Opolon; T Poynard
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

9.  Intestinal dysbiosis: a possible mechanism of alcohol-induced endotoxemia and alcoholic steatohepatitis in rats.

Authors:  Ece Mutlu; Ali Keshavarzian; Phillip Engen; Christopher B Forsyth; Masoumeh Sikaroodi; Patrick Gillevet
Journal:  Alcohol Clin Exp Res       Date:  2009-07-23       Impact factor: 3.455

10.  Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy.

Authors:  Jasmohan S Bajaj; Douglas M Heuman; Arun J Sanyal; Phillip B Hylemon; Richard K Sterling; R Todd Stravitz; Michael Fuchs; Jason M Ridlon; Kalyani Daita; Pamela Monteith; Nicole A Noble; Melanie B White; Andmorgan Fisher; Masoumeh Sikaroodi; Huzefa Rangwala; Patrick M Gillevet
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

View more
  18 in total

1.  Spontaneous Bacterial Peritonitis.

Authors:  Kris Kowdley
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-01

2.  Gut microbiota are linked to increased susceptibility to hepatic steatosis in low-aerobic-capacity rats fed an acute high-fat diet.

Authors:  Matthew R Panasevich; E M Morris; S V Chintapalli; U D Wankhade; K Shankar; S L Britton; L G Koch; J P Thyfault; R S Rector
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-06-10       Impact factor: 4.052

Review 3.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

Review 4.  Gut Microbiota and Hepatocellular Carcinoma.

Authors:  Xueme Tao; Nin Wang; Wenxi Qin
Journal:  Gastrointest Tumors       Date:  2015-04-22

Review 5.  Changes of Intestinal Functions in Liver Cirrhosis.

Authors:  Hiroshi Fukui; Reiner Wiest
Journal:  Inflamm Intest Dis       Date:  2016-03-08

Review 6.  The Microbiome and Sustainable Healthcare.

Authors:  Rodney R Dietert; Janice M Dietert
Journal:  Healthcare (Basel)       Date:  2015-03-03

Review 7.  Implication of the intestinal microbiome in complications of cirrhosis.

Authors:  Mamatha Bhat; Bianca M Arendt; Venkat Bhat; Eberhard L Renner; Atul Humar; Johane P Allard
Journal:  World J Hepatol       Date:  2016-09-28

8.  Myelin as a regulator of development of the microbiota-gut-brain axis.

Authors:  Ciara E Keogh; Danielle H J Kim; Matteo M Pusceddu; Trina A Knotts; Gonzalo Rabasa; Jessica A Sladek; Michael T Hsieh; Mackenzie Honeycutt; Ingrid Brust-Mascher; Mariana Barboza; Mélanie G Gareau
Journal:  Brain Behav Immun       Date:  2020-11-04       Impact factor: 7.217

Review 9.  The digestive tract as the origin of systemic inflammation.

Authors:  Petrus R de Jong; José M González-Navajas; Nicolaas J G Jansen
Journal:  Crit Care       Date:  2016-10-18       Impact factor: 9.097

Review 10.  Gut Microbiota and Host Reaction in Liver Diseases.

Authors:  Hiroshi Fukui
Journal:  Microorganisms       Date:  2015-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.